 | • レポートコード：MRC2Q12-19433 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、尿鎮痙医薬品のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 尿鎮痙医薬品のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 尿鎮痙医薬品の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 尿鎮痙医薬品のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの尿鎮痙医薬品の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の尿鎮痙医薬品の売上および2028年までの予測に焦点を当てています。 尿鎮痙医薬品のグローバル主要企業には、Pfizer、Piramal Pharma Solutions、Allergan、Astellas、Eywa Pharma、Rising Pharmaceuticals、Otto Brandes GmbH、Recordati、Antares Pharma、Accord Healthcare、Heritage Pharmaceuticals、Lannett、Leading Pharma、Major Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 尿鎮痙医薬品市場は、タイプとアプリケーションによって区分されます。世界の尿鎮痙医薬品市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 10mg、20mg、30mg、その他 【アプリケーション別セグメント】 男性、女性 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 尿鎮痙医薬品製品概要 - タイプ別市場（10mg、20mg、30mg、その他） - アプリケーション別市場（男性、女性） - 調査の目的 ・エグゼクティブサマリー - 世界の尿鎮痙医薬品販売量予測2017-2028 - 世界の尿鎮痙医薬品売上予測2017-2028 - 尿鎮痙医薬品の地域別販売量 - 尿鎮痙医薬品の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別尿鎮痙医薬品販売量 - 主要メーカー別尿鎮痙医薬品売上 - 主要メーカー別尿鎮痙医薬品価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（10mg、20mg、30mg、その他） - 尿鎮痙医薬品のタイプ別販売量 - 尿鎮痙医薬品のタイプ別売上 - 尿鎮痙医薬品のタイプ別価格 ・アプリケーション別市場規模（男性、女性） - 尿鎮痙医薬品のアプリケーション別販売量 - 尿鎮痙医薬品のアプリケーション別売上 - 尿鎮痙医薬品のアプリケーション別価格 ・北米市場 - 北米の尿鎮痙医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の尿鎮痙医薬品市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの尿鎮痙医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の尿鎮痙医薬品市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の尿鎮痙医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の尿鎮痙医薬品市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の尿鎮痙医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の尿鎮痙医薬品市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの尿鎮痙医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の尿鎮痙医薬品市場規模（トルコ、サウジアラビア） ・企業情報 Pfizer、Piramal Pharma Solutions、Allergan、Astellas、Eywa Pharma、Rising Pharmaceuticals、Otto Brandes GmbH、Recordati、Antares Pharma、Accord Healthcare、Heritage Pharmaceuticals、Lannett、Leading Pharma、Major Pharmaceuticals ・産業チェーン及び販売チャネル分析 - 尿鎮痙医薬品の産業チェーン分析 - 尿鎮痙医薬品の原材料 - 尿鎮痙医薬品の生産プロセス - 尿鎮痙医薬品の販売及びマーケティング - 尿鎮痙医薬品の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 尿鎮痙医薬品の産業動向 - 尿鎮痙医薬品のマーケットドライバー - 尿鎮痙医薬品の課題 - 尿鎮痙医薬品の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Urinary Antispasodics estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Urinary Antispasodics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Urinary Antispasodics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Urinary Antispasodics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Urinary Antispasodics include Pfizer, Piramal Pharma Solutions, Allergan, Astellas, Eywa Pharma, Rising Pharmaceuticals, Otto Brandes GmbH, Recordati and Antares Pharma, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Urinary Antispasodics companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Urinary Antispasodics market. Further, it explains the major drivers and regional dynamics of the global Urinary Antispasodics market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer
Piramal Pharma Solutions
Allergan
Astellas
Eywa Pharma
Rising Pharmaceuticals
Otto Brandes GmbH
Recordati
Antares Pharma
Accord Healthcare
Heritage Pharmaceuticals
Lannett
Leading Pharma
Major Pharmaceuticals
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Urinary Antispasodics Segment by Type
10 mg
20 mg
30 mg
Others
Urinary Antispasodics Segment by Application
Men
Women
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Urinary Antispasodics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Urinary Antispasodics market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Urinary Antispasodics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Urinary Antispasodics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Urinary Antispasodics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Urinary Antispasodics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Urinary Antispasodics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Piramal Pharma Solutions, Allergan, Astellas, Eywa Pharma, Rising Pharmaceuticals, Otto Brandes GmbH, Recordati and Antares Pharma, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Urinary Antispasodics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urinary Antispasodics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Urinary Antispasodics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Urinary Antispasodics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 10 mg
1.2.3 20 mg
1.2.4 30 mg
1.2.5 Others
1.3 Market by Application
1.3.1 Global Urinary Antispasodics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Men
1.3.3 Women
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Urinary Antispasodics Market Perspective (2017-2028)
2.2 Urinary Antispasodics Growth Trends by Region
2.2.1 Urinary Antispasodics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Urinary Antispasodics Historic Market Size by Region (2017-2022)
2.2.3 Urinary Antispasodics Forecasted Market Size by Region (2023-2028)
2.3 Urinary Antispasodics Market Dynamics
2.3.1 Urinary Antispasodics Industry Trends
2.3.2 Urinary Antispasodics Market Drivers
2.3.3 Urinary Antispasodics Market Challenges
2.3.4 Urinary Antispasodics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Urinary Antispasodics Players by Revenue
3.1.1 Global Top Urinary Antispasodics Players by Revenue (2017-2022)
3.1.2 Global Urinary Antispasodics Revenue Market Share by Players (2017-2022)
3.2 Global Urinary Antispasodics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Urinary Antispasodics Revenue
3.4 Global Urinary Antispasodics Market Concentration Ratio
3.4.1 Global Urinary Antispasodics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Urinary Antispasodics Revenue in 2021
3.5 Urinary Antispasodics Key Players Head office and Area Served
3.6 Key Players Urinary Antispasodics Product Solution and Service
3.7 Date of Enter into Urinary Antispasodics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Urinary Antispasodics Breakdown Data by Type
4.1 Global Urinary Antispasodics Historic Market Size by Type (2017-2022)
4.2 Global Urinary Antispasodics Forecasted Market Size by Type (2023-2028)
5 Urinary Antispasodics Breakdown Data by Application
5.1 Global Urinary Antispasodics Historic Market Size by Application (2017-2022)
5.2 Global Urinary Antispasodics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Urinary Antispasodics Market Size (2017-2028)
6.2 North America Urinary Antispasodics Market Size by Type
6.2.1 North America Urinary Antispasodics Market Size by Type (2017-2022)
6.2.2 North America Urinary Antispasodics Market Size by Type (2023-2028)
6.2.3 North America Urinary Antispasodics Market Share by Type (2017-2028)
6.3 North America Urinary Antispasodics Market Size by Application
6.3.1 North America Urinary Antispasodics Market Size by Application (2017-2022)
6.3.2 North America Urinary Antispasodics Market Size by Application (2023-2028)
6.3.3 North America Urinary Antispasodics Market Share by Application (2017-2028)
6.4 North America Urinary Antispasodics Market Size by Country
6.4.1 North America Urinary Antispasodics Market Size by Country (2017-2022)
6.4.2 North America Urinary Antispasodics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Urinary Antispasodics Market Size (2017-2028)
7.2 Europe Urinary Antispasodics Market Size by Type
7.2.1 Europe Urinary Antispasodics Market Size by Type (2017-2022)
7.2.2 Europe Urinary Antispasodics Market Size by Type (2023-2028)
7.2.3 Europe Urinary Antispasodics Market Share by Type (2017-2028)
7.3 Europe Urinary Antispasodics Market Size by Application
7.3.1 Europe Urinary Antispasodics Market Size by Application (2017-2022)
7.3.2 Europe Urinary Antispasodics Market Size by Application (2023-2028)
7.3.3 Europe Urinary Antispasodics Market Share by Application (2017-2028)
7.4 Europe Urinary Antispasodics Market Size by Country
7.4.1 Europe Urinary Antispasodics Market Size by Country (2017-2022)
7.4.2 Europe Urinary Antispasodics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Urinary Antispasodics Market Size (2017-2028)
8.2 Asia-Pacific Urinary Antispasodics Market Size by Type
8.2.1 Asia-Pacific Urinary Antispasodics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Urinary Antispasodics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Urinary Antispasodics Market Share by Type (2017-2028)
8.3 Asia-Pacific Urinary Antispasodics Market Size by Application
8.3.1 Asia-Pacific Urinary Antispasodics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Urinary Antispasodics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Urinary Antispasodics Market Share by Application (2017-2028)
8.4 Asia-Pacific Urinary Antispasodics Market Size by Region
8.4.1 Asia-Pacific Urinary Antispasodics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Urinary Antispasodics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Urinary Antispasodics Market Size (2017-2028)
9.2 Latin America Urinary Antispasodics Market Size by Type
9.2.1 Latin America Urinary Antispasodics Market Size by Type (2017-2022)
9.2.2 Latin America Urinary Antispasodics Market Size by Type (2023-2028)
9.2.3 Latin America Urinary Antispasodics Market Share by Type (2017-2028)
9.3 Latin America Urinary Antispasodics Market Size by Application
9.3.1 Latin America Urinary Antispasodics Market Size by Application (2017-2022)
9.3.2 Latin America Urinary Antispasodics Market Size by Application (2023-2028)
9.3.3 Latin America Urinary Antispasodics Market Share by Application (2017-2028)
9.4 Latin America Urinary Antispasodics Market Size by Country
9.4.1 Latin America Urinary Antispasodics Market Size by Country (2017-2022)
9.4.2 Latin America Urinary Antispasodics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Urinary Antispasodics Market Size (2017-2028)
10.2 Middle East & Africa Urinary Antispasodics Market Size by Type
10.2.1 Middle East & Africa Urinary Antispasodics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Urinary Antispasodics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Urinary Antispasodics Market Share by Type (2017-2028)
10.3 Middle East & Africa Urinary Antispasodics Market Size by Application
10.3.1 Middle East & Africa Urinary Antispasodics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Urinary Antispasodics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Urinary Antispasodics Market Share by Application (2017-2028)
10.4 Middle East & Africa Urinary Antispasodics Market Size by Country
10.4.1 Middle East & Africa Urinary Antispasodics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Urinary Antispasodics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Urinary Antispasodics Introduction
11.1.4 Pfizer Revenue in Urinary Antispasodics Business (2017-2022)
11.1.5 Pfizer Recent Developments
11.2 Piramal Pharma Solutions
11.2.1 Piramal Pharma Solutions Company Details
11.2.2 Piramal Pharma Solutions Business Overview
11.2.3 Piramal Pharma Solutions Urinary Antispasodics Introduction
11.2.4 Piramal Pharma Solutions Revenue in Urinary Antispasodics Business (2017-2022)
11.2.5 Piramal Pharma Solutions Recent Developments
11.3 Allergan
11.3.1 Allergan Company Details
11.3.2 Allergan Business Overview
11.3.3 Allergan Urinary Antispasodics Introduction
11.3.4 Allergan Revenue in Urinary Antispasodics Business (2017-2022)
11.3.5 Allergan Recent Developments
11.4 Astellas
11.4.1 Astellas Company Details
11.4.2 Astellas Business Overview
11.4.3 Astellas Urinary Antispasodics Introduction
11.4.4 Astellas Revenue in Urinary Antispasodics Business (2017-2022)
11.4.5 Astellas Recent Developments
11.5 Eywa Pharma
11.5.1 Eywa Pharma Company Details
11.5.2 Eywa Pharma Business Overview
11.5.3 Eywa Pharma Urinary Antispasodics Introduction
11.5.4 Eywa Pharma Revenue in Urinary Antispasodics Business (2017-2022)
11.5.5 Eywa Pharma Recent Developments
11.6 Rising Pharmaceuticals
11.6.1 Rising Pharmaceuticals Company Details
11.6.2 Rising Pharmaceuticals Business Overview
11.6.3 Rising Pharmaceuticals Urinary Antispasodics Introduction
11.6.4 Rising Pharmaceuticals Revenue in Urinary Antispasodics Business (2017-2022)
11.6.5 Rising Pharmaceuticals Recent Developments
11.7 Otto Brandes GmbH
11.7.1 Otto Brandes GmbH Company Details
11.7.2 Otto Brandes GmbH Business Overview
11.7.3 Otto Brandes GmbH Urinary Antispasodics Introduction
11.7.4 Otto Brandes GmbH Revenue in Urinary Antispasodics Business (2017-2022)
11.7.5 Otto Brandes GmbH Recent Developments
11.8 Recordati
11.8.1 Recordati Company Details
11.8.2 Recordati Business Overview
11.8.3 Recordati Urinary Antispasodics Introduction
11.8.4 Recordati Revenue in Urinary Antispasodics Business (2017-2022)
11.8.5 Recordati Recent Developments
11.9 Antares Pharma
11.9.1 Antares Pharma Company Details
11.9.2 Antares Pharma Business Overview
11.9.3 Antares Pharma Urinary Antispasodics Introduction
11.9.4 Antares Pharma Revenue in Urinary Antispasodics Business (2017-2022)
11.9.5 Antares Pharma Recent Developments
11.10 Accord Healthcare
11.10.1 Accord Healthcare Company Details
11.10.2 Accord Healthcare Business Overview
11.10.3 Accord Healthcare Urinary Antispasodics Introduction
11.10.4 Accord Healthcare Revenue in Urinary Antispasodics Business (2017-2022)
11.10.5 Accord Healthcare Recent Developments
11.11 Heritage Pharmaceuticals
11.11.1 Heritage Pharmaceuticals Company Details
11.11.2 Heritage Pharmaceuticals Business Overview
11.11.3 Heritage Pharmaceuticals Urinary Antispasodics Introduction
11.11.4 Heritage Pharmaceuticals Revenue in Urinary Antispasodics Business (2017-2022)
11.11.5 Heritage Pharmaceuticals Recent Developments
11.12 Lannett
11.12.1 Lannett Company Details
11.12.2 Lannett Business Overview
11.12.3 Lannett Urinary Antispasodics Introduction
11.12.4 Lannett Revenue in Urinary Antispasodics Business (2017-2022)
11.12.5 Lannett Recent Developments
11.13 Leading Pharma
11.13.1 Leading Pharma Company Details
11.13.2 Leading Pharma Business Overview
11.13.3 Leading Pharma Urinary Antispasodics Introduction
11.13.4 Leading Pharma Revenue in Urinary Antispasodics Business (2017-2022)
11.13.5 Leading Pharma Recent Developments
11.14 Major Pharmaceuticals
11.14.1 Major Pharmaceuticals Company Details
11.14.2 Major Pharmaceuticals Business Overview
11.14.3 Major Pharmaceuticals Urinary Antispasodics Introduction
11.14.4 Major Pharmaceuticals Revenue in Urinary Antispasodics Business (2017-2022)
11.14.5 Major Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer